Pharmacotherapy of obsessive-compulsive disorder: Experience with the selective serotonin reuptake inhibitors

B. Vythilingum, C. Cartwright, Eric Hollander

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Since the introduction of the selective serotonin reuptake inhibitors (SSRIs) a decade ago, they have become first-line agents in the treatment of obsessive-compulsive disorder (OCD). Numerous clinical trials have confirmed their efficacy, and established their superior risk-benefit ratio in comparison with clomipramine, a non-selective serotonin reuptake inhibitor. Relatively higher doses and longer duration of treatment may be necessary to effect a response in OCD, with long-term treatment being required to maintain therapeutic gains. Despite the advances represented by the SSRIs, treatment resistance remains a problem. While no one solution exists, various strategies, including pharmacotherapy augmentation, look promising. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
JournalInternational Clinical Psychopharmacology
Volume15
Issue numberSUPPL. 2
StatePublished - 2000
Externally publishedYes

Fingerprint

Obsessive-Compulsive Disorder
Serotonin Uptake Inhibitors
Drug Therapy
Therapeutics
Clomipramine
Odds Ratio
Clinical Trials

Keywords

  • Obsessive-compulsive disorder
  • Pharmacotherapy
  • Serotonin
  • SRIs
  • SSRIs

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacotherapy of obsessive-compulsive disorder : Experience with the selective serotonin reuptake inhibitors. / Vythilingum, B.; Cartwright, C.; Hollander, Eric.

In: International Clinical Psychopharmacology, Vol. 15, No. SUPPL. 2, 2000.

Research output: Contribution to journalArticle

@article{7ba33f1a1c614f17898876027120e217,
title = "Pharmacotherapy of obsessive-compulsive disorder: Experience with the selective serotonin reuptake inhibitors",
abstract = "Since the introduction of the selective serotonin reuptake inhibitors (SSRIs) a decade ago, they have become first-line agents in the treatment of obsessive-compulsive disorder (OCD). Numerous clinical trials have confirmed their efficacy, and established their superior risk-benefit ratio in comparison with clomipramine, a non-selective serotonin reuptake inhibitor. Relatively higher doses and longer duration of treatment may be necessary to effect a response in OCD, with long-term treatment being required to maintain therapeutic gains. Despite the advances represented by the SSRIs, treatment resistance remains a problem. While no one solution exists, various strategies, including pharmacotherapy augmentation, look promising. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Obsessive-compulsive disorder, Pharmacotherapy, Serotonin, SRIs, SSRIs",
author = "B. Vythilingum and C. Cartwright and Eric Hollander",
year = "2000",
language = "English (US)",
volume = "15",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Pharmacotherapy of obsessive-compulsive disorder

T2 - Experience with the selective serotonin reuptake inhibitors

AU - Vythilingum, B.

AU - Cartwright, C.

AU - Hollander, Eric

PY - 2000

Y1 - 2000

N2 - Since the introduction of the selective serotonin reuptake inhibitors (SSRIs) a decade ago, they have become first-line agents in the treatment of obsessive-compulsive disorder (OCD). Numerous clinical trials have confirmed their efficacy, and established their superior risk-benefit ratio in comparison with clomipramine, a non-selective serotonin reuptake inhibitor. Relatively higher doses and longer duration of treatment may be necessary to effect a response in OCD, with long-term treatment being required to maintain therapeutic gains. Despite the advances represented by the SSRIs, treatment resistance remains a problem. While no one solution exists, various strategies, including pharmacotherapy augmentation, look promising. (C) 2000 Lippincott Williams and Wilkins.

AB - Since the introduction of the selective serotonin reuptake inhibitors (SSRIs) a decade ago, they have become first-line agents in the treatment of obsessive-compulsive disorder (OCD). Numerous clinical trials have confirmed their efficacy, and established their superior risk-benefit ratio in comparison with clomipramine, a non-selective serotonin reuptake inhibitor. Relatively higher doses and longer duration of treatment may be necessary to effect a response in OCD, with long-term treatment being required to maintain therapeutic gains. Despite the advances represented by the SSRIs, treatment resistance remains a problem. While no one solution exists, various strategies, including pharmacotherapy augmentation, look promising. (C) 2000 Lippincott Williams and Wilkins.

KW - Obsessive-compulsive disorder

KW - Pharmacotherapy

KW - Serotonin

KW - SRIs

KW - SSRIs

UR - http://www.scopus.com/inward/record.url?scp=0033752730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033752730&partnerID=8YFLogxK

M3 - Article

C2 - 11110014

AN - SCOPUS:0033752730

VL - 15

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - SUPPL. 2

ER -